News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (303 of 347). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (11 of 347). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (33 of 347). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 265 of 347 items have one.
Safe, low-cost Alzheimer's drug demonstrates efficacy against sickle cell anemia
Memantine, a long-approved and cost-effective drug used to treat Alzheimer's disease, could also benefit patients with sickle cell anemia in the future. …
Why it matters: Memantine, a long-approved and cost-effective Alzheimer's drug, shows potential to benefit patients with sickle cell anemia in the future.
Read at Medical Xpress →NIA statement on the U.S. Cost of Dementia Model report
Read an announcement about an NIA-funded project that reports the economic burden of Alzheimer's disease and related dementia in the United States.
Why it matters: An NIA-funded project reports the economic burden of Alzheimer's disease and related dementia in the United States.
Read at NIH National Institute on Aging → Archived copy (2 Aug 2026), Internet ArchiveReview of Medicare data reveals potential new statistics on dementia diagnosis
A study of Medicare data showed that roughly 9% of beneficiaries — 5.3 million people — may have Alzheimer’s disease or a related dementia.
Why it matters: A review of Medicare data indicates that approximately 9 percent of beneficiaries, totaling 5.3 million people, may have Alzheimer’s disease or a related dementia.
Follow new items in a feed reader: Atom feed.